Lung cancer study: which targeted drug works best for rare mutation?
Disease control
Not yet recruiting
This study compares two types of targeted therapy (first-generation vs third-generation EGFR TKIs) for people with advanced lung cancer that has a specific rare mutation called EGFR exon 19 deletion-insertion. About 94 participants will be randomly assigned to one of the two trea…
Phase: EARLY_PHASE1 • Sponsor: Fuzhou General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC